Loading company…
Prilenia Therapeutics B.V., based in Herzliya, Israel, is a clinical-stage biotech developing therapies for Huntington's disease and ALS.
Founded in 2018 in Herzliya, Israel, Prilenia Therapeutics B.V. is a clinical-stage biotechnology company focused on neurodegenerative diseases, particularly Huntington's disease and Amyotrophic Lateral Sclerosis (ALS). Its lead product, Pridopidine, is in clinical trials, and the company works with pharmaceutical partners, healthcare providers, and research institutions in North America and Europe. Its Series B round raised USD 10.000 mn from investors including Amplitude and Forbion, and CEO Limor Har leads the company. The company has also secured venture funding from MaasInvest.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in